Abiopharma

Share Buy Back - Daily Share Buy-Back Notice: Daily Share Buy-Back Notice 15 June 2026

I risultati dello studio clinico pivotale di Fase 3 frontMIND di Incyte sulla combinazione di Tafasitamab (Monjuvi®/Minjuvi®) presentati in occasione della sessione plenaria del congresso 2026 della European Hematology Association (EHA)...

De resultaten van Incyte’s cruciale fase 3-studie frontMIND naar de combinatiebehandeling met tafasitamab (Monjuvi® /Minjuvi®) werden gepresenteerd tijdens de plenaire sessie van het congres van de European Hematology Association (EHA)...

Los resultados del ensayo fundamental frontMIND fase 3 de la combinación tafasitamab (Monjuvi®/Minjuvi®) de Incyte presentados en el plenario del Congreso de la Asociación Europea de Hematología (EHA) 2026...

Ergebnisse der zulassungsrelevanten Phase-3-Studie „frontMIND“ von Incyte zur Kombination von Tafasitamab (Monjuvi® /Minjuvi® ), die auf der Plenarsitzung des Kongresses der European Hematology Association (EHA) 2026 vorgestellt wurden...

Les résultats de l’essai pivot de phase 3 frontMIND mené par Incyte sur l’association thérapeutique à base de tafasitamab (Monjuvi®/Minjuvi®), présentés lors de la séance plénière du congrès 2026 de l’Association européenne d’hématologie (EHA)...

Shareholder Alert: Ademi LLP investigates whether Payoneer Global Inc. is obtaining a Fair Price for Public Shareholders

General Announcement: Rights Issue - Update on Irrevocable Undertaking and Amendments to Offer Information Statement

Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer: Changes in Interest of Director - Koh Wee Seng

Disclosure of Interest/ Changes in Interest of Substantial Shareholder(s)/ Unitholder(s): Changes in Interest of Substantial Shareholders - ACL and MLHS